{"id":"W4388033279","doi":"10.1177/13524585231205708","title":"Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital; Ottawa Hospital; McGill University; NeuroRx Research (Canada); University of Ottawa; University of Toronto; Montreal Neurological Institute and Hospital","funders":"Academy of Military Medical Sciences; Chugai Pharmaceutical; EMD Serono; Eisai; Deutsche Forschungsgemeinschaft; Genentech; Horizon Therapeutics; TG Therapeutics; H. Lundbeck A/S; BeiGene; Federalno Ministarstvo Obrazovanja i Nauke; European Committee for Treatment and Research in Multiple Sclerosis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Greenwich Biosciences; Alexion Pharmaceuticals; Bundesministerium für Bildung und Forschung; Teva Pharmaceutical Industries; Celgene; Pfizer; Biogen; CSL Behring Foundation for Research and Advancement of Patient Health; Sanofi","keywords":"Tolerability; Dimethyl fumarate; Medicine; Multiple sclerosis; Adverse effect; Relapsing remitting; Clinical endpoint; Confidence interval; Internal medicine; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.003687955,0.0007625919,0.001227304,0.0005813765,0.001817006,0.0004534051,0.0006155731,0.0002066822,0.00006523934],"category_scores_gemma":[0.008989276,0.000498993,0.0002559137,0.001750226,0.00049885,0.0005740162,0.0006642563,0.002114654,0.00008553065],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004620384,"about_ca_system_score_gemma":0.0002012226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009912009,"about_ca_topic_score_gemma":0.0009639624,"domain_scores_codex":[0.9922901,0.0009148116,0.001863838,0.00124732,0.002165843,0.001518052],"domain_scores_gemma":[0.9925873,0.004268201,0.0007209181,0.001057969,0.0006774268,0.0006881381],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0197286,0.003362278,0.9091766,0.00002483282,0.0005685134,0.00005588731,0.007375858,0.0005327537,0.004081854,3.48732e-7,0.002353532,0.05273896],"study_design_scores_gemma":[0.1162573,0.001779688,0.8684187,0.002171821,0.0001836724,0.000006546403,0.003190103,0.006964405,0.0001903268,0.000003081268,0.0003616335,0.0004727223],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993982,0.0004546719,0.00005903983,0.001586008,0.0003668889,0.002746011,0.0005139979,0.0002038864,0.00008749632],"genre_scores_gemma":[0.9960496,0.001584736,0.001070723,0.0001825381,0.0005488587,0.00009115948,0.0002136803,0.0001357891,0.0001228673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09652872,"threshold_uncertainty_score":0.9997461,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1290231358133592,"score_gpt":0.3116451762617941,"score_spread":0.1826220404484348,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}